An Alzheimer’s drug manufactured by Eli Lilly has shown to slow down the rate that patients lose their ability to think and care for themselves. This was a small clinical trial with 272 patients and has not yet been published or widely reviewed. However, if the findings are true, then this would be the first drug to have a positive outcome in Phase 2 trials. Other Alzheimer’s drugs were never tested in Phase 2 because they either moved straight into Phase 3 or didn’t have positive results. Participants in the study showed the rate of decline to slow by 32% compared to patients who received the placebo. Click here to read the full article by Gina Kolata.